Want to see AU:OSX full AI Analyst Report?
Osteopore Ltd. (OSX) AI Stock Analysis
Top Page
Osteopore Ltd.
(ASX:OSX)
The score is driven primarily by weak financial performance: ongoing losses, continued cash burn, and negative equity outweigh strong revenue growth and reduced debt. Technical and valuation inputs are largely unavailable or not meaningful (missing indicators; negative P/E and no dividend yield), contributing a neutral-to-slightly negative impact.
Osteopore Ltd. (OSX) vs. iShares MSCI Australia ETF (EWA)
- Market Cap
- AUD 1.25M
- Dividend Yield
- ―
- Average Volume (3M)
- ―
- Price to Earnings (P/E)
- -0.3
- Beta (1Y)
- 0.39
- Revenue Growth
- 2.86%
- EPS Growth
- 38.24%
- Country
- Australia
- Employees
- 15
- Sector
- Healthcare
- Sector Strength
- 51
- Industry
- Medical - Instruments & Supplies
Osteopore Ltd. Business Overview & Revenue Model
Company Description
Established in Singapore in 2003, Osteopore Limited focuses on engineering, manufacturing, and globally commercializing bioresorbable polymer implants. These advanced devices are utilized in neurosurgical, orthopedic, and maxillofacial operations thr...
How the Company Makes Money
Osteopore primarily makes money by selling its bioresorbable scaffold implants and related surgical products for use in patient procedures. Revenue is generated when hospitals/clinics (or their procurement groups) purchase Osteopore’s implants either...
Osteopore Ltd. Financial Statement Overview
Summary
Despite strong multi-year revenue growth and a healthy 2025 gross margin (~53%), the company remains high-risk financially due to deeply negative operating/net margins, continued sizable net losses (~3.7M in 2025), persistent negative operating/free cash flow (~-2.6M in 2025), and a shift to negative equity (~-1.7M) in 2025 (reduced financial flexibility), partially offset by sharply lower debt (~0.2M vs ~1.3M in 2024).
Income Statement
28NegativeBalance Sheet
22NegativeCash Flow
18Very Negative| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 2.93M | 3.06M | 2.81M | 2.22M | 1.69M | 1.11M |
| Gross Profit | 1.83M | 1.62M | 2.37M | 1.64M | 1.27M | 811.64K |
| EBITDA | -2.34M | -1.92M | -2.29M | -4.35M | -3.97M | -3.38M |
| Net Income | -4.11M | -3.72M | -3.35M | -4.87M | -4.22M | -3.62M |
Balance Sheet | ||||||
| Total Assets | 3.39M | 2.77M | 3.13M | 3.34M | 3.62M | 6.01M |
| Cash, Cash Equivalents and Short-Term Investments | 1.25M | 626.97K | 638.50K | 1.16M | 1.35M | 4.55M |
| Total Debt | 74.39K | 198.80K | 1.33M | 1.09M | 74.18K | 106.71K |
| Total Liabilities | 5.19M | 4.50M | 2.83M | 2.91M | 1.51M | 633.40K |
| Stockholders Equity | -1.80M | -1.73M | 306.22K | 432.60K | 2.11M | 5.37M |
Cash Flow | ||||||
| Free Cash Flow | -2.21M | -2.57M | -3.10M | -3.74M | -4.06M | -4.00M |
| Operating Cash Flow | -2.17M | -2.56M | -3.09M | -3.74M | -4.00M | -3.81M |
| Investing Cash Flow | -78.45K | -10.79K | -14.59K | -7,365 | -63.98K | -194.62K |
| Financing Cash Flow | 1.67M | 2.67M | 2.63M | 3.58M | 896.32K | -485.88K |
Osteopore Ltd. Peers Comparison
Overall Rating
AU:PNV75Outperform
AU:ARX51Neutral
AU:CMB51Neutral
AU:OCC50Neutral- AU:OSX42Neutral
AU:TRP32Underperform
Financial Indicators
| Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| AU:PNV | 75Outperform | AUD 625.21M | 85.38 | 8.45% | ― | 12.94% | -44.50% |
| Sector * | 51Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
| AU:ARX | 51Neutral | AUD 190.25M | 45.83 | 4.96% | ― | 19.23% | ― |
| AU:CMB | 51Neutral | AUD 11.77M | -1.59 | -247.44% | ― | -4.24% | 33.39% |
| AU:OCC | 50Neutral | AUD 149.82M | -10.38 | -36.83% | ― | 51.07% | -47.63% |
| AU:OSX | 42Neutral | AUD 2.77M | -0.27 | 232.78% | ― | 2.86% | 38.24% |
| AU:TRP | 32Underperform | AUD 5.06M | -1.07 | -52.04% | ― | 32.22% | -26.53% |
* Healthcare Sector Average
Performance Comparison
| Show on chart | Ticker | Company Name | Price | Change | % Change |
|---|---|---|---|---|---|
| AU:OSX | Osteopore Ltd. | 0.01 | 0.00 | 0.00% | |
| AU:PNV | Polynovo Limited | 0.91 | -0.36 | -28.46% | |
| AU:OCC | Orthocell Ltd | 0.55 | -0.64 | -53.78% | |
| AU:TRP | Tissue Repair Ltd | 0.10 | -0.24 | -71.21% | |
| AU:CMB | Regeneus Ltd. | 0.40 | -0.09 | -19.19% | |
| AU:ARX | Aroa Biosurgery Ltd | 0.55 | -0.25 | -31.25% |
Osteopore Ltd. Corporate Events
Osteopore switches auditors to Pitcher Partners to bolster governance
Osteopore Limited has appointed Pitcher Partners BA&A Pty Ltd as its new external auditor, effective 31 July 2026, following the resignation of Grant Thornton Audit Pty Ltd and approval of the change by ASIC under the Corporations Act. The board...
Osteopore Misses Q2 Targets but Gains Asian Orthopaedic Approvals
Osteopore reported quarterly revenue of AUD 676,000 for the three months to 30 June 2026, with performance slightly below expectations due to slower-than-anticipated uptake of its custom-made cranioplasty products and ongoing distribution transitions...
Osteopore Seeks ASX Quotation for 15.2 Million New Shares
Osteopore Ltd has applied to the ASX for quotation of 15,151,515 new ordinary fully paid shares under its existing OSX ticker, with an issue date of 23 July 2026. The additional share quotation expands the company’s listed equity base, which ma...
Osteopore Gains Saudi Arabia Market Access for Craniofacial Implants
Osteopore has secured market access to Saudi Arabia for its craniofacial implants via its distribution partnership with Zimmer Biomet, expanding on earlier launches in Europe, Australia and Hong Kong that have already driven a three-fold increase in...
Osteopore Treats First Patient in Jaw Reconstruction Implant Trial
Osteopore has reported the successful treatment of the first patient in a jaw reconstruction clinical trial at Brisbane’s Princess Alexandra Hospital, using its novel 3D-printed bioresorbable implant tailored to the patient’s anatomy. The...
Osteopore advances paediatric cleft lip trial with first implants at Queensland Children’s Hospital
Osteopore Limited has reported that the first two paediatric patients in its cleft lip augmentation clinical trial at Queensland Children’s Hospital have successfully received their 3D-printed bioresorbable implants. The single-arm feasibility...
Osteopore Completes Patient Recruitment for Cleft Lip Implant Trial at Queensland Children’s Hospital
Osteopore has completed recruitment of all five paediatric patients for a Queensland Children’s Hospital clinical trial evaluating its 3D-printed bioresorbable scaffolds for paranasal augmentation in children with unilateral cleft lip. The stud...
Osteopore Wins Neurosurgery Product Approval at Major Thai Medical Centre
Osteopore Ltd has secured approval for its neurosurgery products at Thammasat University Hospital, a major teaching and tertiary care centre in Bangkok serving thousands of outpatients daily and operating more than 800 inpatient beds. The move follow...
Osteopore Issues Additional Unquoted Convertible Notes
Osteopore Ltd has notified the market of the issuance of additional unquoted convertible notes, with five securities recorded under its OSXAM convertible notes line. The notes were issued on June 22, 2026, and the filing formalises this capital-relat...
Osteopore Extends Tranche 2 Drawdown in A$20m Note Program
Osteopore Limited has continued to draw on its previously arranged funding facility, confirming that subscribers have taken up an additional sub-tranche of Tranche 2 redeemable convertible notes worth A$250,000. This latest drawdown lifts the company...
Osteopore Marks First Custom Orthopaedic Reconstruction in Hong Kong
Osteopore has completed its first custom orthopaedic reconstruction case in Hong Kong, using a 3D-printed bioresorbable implant to correct a wrist deformity at Queen Mary Hospital under Clinical Associate Professor Christian Fang. The custom implant...
Osteopore Ships First Dental Order Under DKSH Deal to Tap Malaysia’s Growing Regeneration Market
Osteopore has delivered its first batch of dental products in Malaysia under a five-year distribution partnership with DKSH, marking the start of commercial activities for its dental portfolio in the country. The off-the-shelf products, used in Guide...
Advance Opportunities Fund I exits substantial holding in Osteopore
Osteopore Limited has disclosed that Advance Opportunities Fund I has ceased to be a substantial shareholder in the company, following a series of on-market share sales. According to the notice filed under the Corporations Act, the fund gradually red...
Osteopore Seeks ASX Quotation for Over 52 Million New Shares
Osteopore Limited has applied for quotation on the ASX of 52,083,333 new ordinary fully paid shares, which were issued on 5 June 2026. The additional securities expand the company’s quoted share capital and may provide greater liquidity and fun...
Osteopore Backs New Cleft Lip Trial With 3D-Printed Implants at QCH
Osteopore Ltd and Queensland Children’s Hospital have launched a single-arm feasibility clinical trial using Osteopore’s 3D-printed, bioresorbable mPCL-TCP scaffolds for paranasal augmentation in up to five paediatric patients with unilat...
Osteopore Wins Hainan Approval, Opening Fast-Track Route Into China Orthopaedics Market
Osteopore Ltd has secured approval from the Hainan Medical Products Administration for the clinical use and sale of its custom orthopaedic medical devices at the Hainan branch of Shanghai Ruijin Hospital, within China’s Boao Lecheng Internation...
Osteopore Wins Strong Shareholder Backing at AGM, Secures 10% Placement Facility
Osteopore Limited reported that all resolutions put to shareholders at its Annual General Meeting on 21 May 2026 were passed on a poll, including a special resolution approving a 10% placement facility. Investors strongly backed the remuneration repo...
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.
Date of analysis: Aug 04, 2026